SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kim JP. Surgical results in gastric cancer. Semin Surg Oncol. 1999; 17: 132138.
  • 2
    MacDonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345: 725730.
  • 3
    Smalley SR, Gunderson L, Tepper J, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys. 2002; 52: 283293.
  • 4
    Lawrence TS, Ten Haken RK, Kessler ML, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys. 1992; 23: 781788.
  • 5
    Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002; 53: 810821.
  • 6
    Cheng JC, Wu JK, Huang CM, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys. 2002; 54: 156162.
  • 7
    Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000; 62: 299307.
  • 8
    Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47: 1347.
  • 9
    Lyman JT. Complication probability as assessed from dose volume histograms. Radiat Res. 1985; 8 (Suppl): 513519.
  • 10
    Cox D, Snell E. Analysis of binary data. New York: Chapman and Hall, 1989.
  • 11
    Roberts SA, Hendry JH. The delay before onset of accelerated tumour cell repopulation during radiotherapy: a direct maximum-likelihood analysis of a collection of worldwide tumour-control data. Radiother Oncol. 1993; 29: 6974.
  • 12
    Seydel HG, Stablein DM, Leichman LP, Kinzie JJ, Thomas PR. Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience. Cancer. 1990; 65: 14781482.
  • 13
    Evans DB, Abbruzzese JL, Cleary KR, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation. Int J Radiat Oncol Biol Phys. 1995; 33: 913918.
  • 14
    Abrams RA, Grochow LB, Chakravarthy A, et al. Intensified adjuvant therapy for pancreatic and preiampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys. 1999; 44: 10391046.
  • 15
    Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001; 24: 9195.
  • 16
    Regine WF, John WJ, McGrath P, Strodel WE, Mohiuddin M. The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma. J Hepatobiliary Pancreat Surg. 2000; 7: 5357.
  • 17
    Whittington R, Neuberg D, Tester WJ, Benson AB III, Haller DG. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a Phase I Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995; 13: 227232.
  • 18
    Komaki R, Wadler S, Peters T, et al. High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi-institutional trial (Radiation Therapy Oncology Group Protocol 8801). Cancer. 1992; 69: 28072812.
  • 19
    Kastl S, Brunner T, Herrmann O, et al. Neoadjuvant radio-chemotherapy in advanced primarily non-resectable carcinomas of the pancreas. Eur J Surg Oncol. 2000; 26: 578582.
  • 20
    Kretzschmar A, Reichardt P, Thuss-Patience PC, et al. Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer. Oncology. 2000; 59: 1417.
  • 21
    Kollmannsberger C, Quietzsch D, Haag C, et al. A Phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer. 2000; 83: 458462.
  • 22
    Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995; 31: 12371248.
  • 23
    Cheng JC, Chuang VP, Cheng SH, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2000; 47: 435442.
  • 24
    Cheng JC, Wu JK, Huang CM, et al. Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol. 2002; 63: 4145.
  • 25
    Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol. 2001; 65: 473477.
  • 26
    Tsai SL, Chen PJ, Lai MY, et al. Acute exacerbation of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J Clin Invest. 1992; 89: 8796.
  • 27
    Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ, Bagshawe KD. Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet. 1975; 2: 528530.
  • 28
    Hoofnagle JH, Dusheiko GM, Schafter DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med. 1982; 96: 447449.
  • 29
    Yeo W, Zhong S, Chan PK, et al. Sequence variations of precore/core and precore promotor regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. J Viral Hepatol. 2000; 7: 448458.
  • 30
    Yeo W, Steinberg JL, Tam JS, et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol. 1999; 59: 263269.
  • 31
    Yamada K, Soejima T, Sugimoto K, et al. Pilot study of local radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Jpn J Clin Oncol. 2001; 31: 147152.